efavirenz and dpc 083

efavirenz has been researched along with dpc 083 in 5 studies

Research

Studies (5)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	4 (80.00)	29.6817
2010's	1 (20.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Anderson, PS; Bacheler, LT; Corbett, JW; Cordova, BC; Diamond, S; Erickson-Viitanen, SK; Garber, S; Gearhart, LA; Jeffrey, S; Klabe, RM; Ko, SS; Logue, K; Magnus, NA; Rodgers, JD; Trainor, GL	1
Corbett, JW; Cordova, BC; Erickson-Viitanen, SK; Garber, S; Klabe, RM; Markwalder, JA; Pan, S; Rodgers, JD	1
Corbett, JW; Cordova, BC; Erickson-Viitanen, SK; Klabe, RM; Kresge, KJ; Pan, S; Rodgers, JD	1
Bacheler, LT; Chidester, DR; Cocuzza, AJ; Cordova, BC; Diamond, S; Erickson-Viitanen, SK; Jeffrey, S; Klabe, RM; Ko, SS; Rodgers, JD; Weigelt, CA	1
Bastos, MM; Bezerra, TC; Boechat, N; Costa, CCP; da Silva, FC	1

Reviews

1 review(s) available for efavirenz and dpc 083

Article	Year
Efavirenz a nonnucleoside reverse transcriptase inhibitor of first-generation: Approaches based on its medicinal chemistry. European journal of medicinal chemistry, 2016, Jan-27, Volume: 108 Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Chemistry, Pharmaceutical; Cyclopropanes; HIV Reverse Transcriptase; HIV-1; Humans; Molecular Conformation; Reverse Transcriptase Inhibitors; Structure-Activity Relationship	2016

Article

Year

Efavirenz a nonnucleoside reverse transcriptase inhibitor of first-generation: Approaches based on its medicinal chemistry.

European journal of medicinal chemistry, 2016, Jan-27, Volume: 108

Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Chemistry, Pharmaceutical; Cyclopropanes; HIV Reverse Transcriptase; HIV-1; Humans; Molecular Conformation; Reverse Transcriptase Inhibitors; Structure-Activity Relationship

2016

Other Studies

4 other study(ies) available for efavirenz and dpc 083

Article	Year
Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors. Journal of medicinal chemistry, 2000, May-18, Volume: 43, Issue:10 Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Blood Proteins; Cyclopropanes; HIV Reverse Transcriptase; HIV-1; Humans; Molecular Structure; Mutation; Oxazines; Protein Binding; Quinazolines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Virus Replication	2000
3,3a-Dihydropyrano[4,3,2-de]quinazolin-2(1H)-ones are potent non-nucleoside reverse transcriptase inhibitors. Bioorganic & medicinal chemistry letters, 2001, Jan-22, Volume: 11, Issue:2 Topics: Binding Sites; Combinatorial Chemistry Techniques; Drug Resistance; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, 3-Ring; HIV Reverse Transcriptase; Humans; Inhibitory Concentration 50; Models, Molecular; Point Mutation; Pyrans; Quinazolines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship	2001
Trifluoromethyl-containing 3-alkoxymethyl- and 3-aryloxymethyl-2-pyridinones are potent inhibitors of HIV-1 non-nucleoside reverse transcriptase. Bioorganic & medicinal chemistry letters, 2001, Feb-12, Volume: 11, Issue:3 Topics: Anti-HIV Agents; Combinatorial Chemistry Techniques; Cytopathogenic Effect, Viral; Enzyme Inhibitors; Fluorine; HIV Reverse Transcriptase; HIV-1; Inhibitory Concentration 50; Mutation; Pyridones; Structure-Activity Relationship	2001
4,1-Benzoxazepinone analogues of efavirenz (Sustiva) as HIV-1 reverse transcriptase inhibitors. Bioorganic & medicinal chemistry letters, 2001, Jun-04, Volume: 11, Issue:11 Topics: Alkynes; Animals; Benzoxazines; Cyclopropanes; HIV Reverse Transcriptase; Humans; Macaca mulatta; Oxazines; Protein Binding; Quinazolines; Quinazolinones; Reverse Transcriptase Inhibitors; Structure-Activity Relationship	2001